Anavex Life Sciences receives Nasdaq delinquency notice for late 10-Q filing

Anavex Life Sciences received a delinquency notification from Nasdaq on May 20, 2026, due to failure to timely file its Form 10-Q for Q2 2026, and has until July 20, 2026 to submit a compliance plan. The notification has no immediate effect on the company's stock listing but signals regulatory compliance issues for the clinical-stage biopharmaceutical firm.